On May 13, 2020, Dai Tao, deputy director of the Medical and Health Science and Technology Development Research Center of the National Health Commission, Zheng Ying, a researcher at the Health Policy Research Center of the Chinese Academy of Medical Sciences, and Xi Kebo, deputy director of the Science, Technology, Education and International Cooperation Department of the Municipal Health Bureau, and a group of 8 people went to Beike Bio to investigate the construction and development of health technology innovation. Dr. Hu Junyuan, chairman of Beike Bio, warmly received them.
At the research symposium, Dr. Hu Junyuan, chairman of Beike Biotech, introduced to the research group the innovative results achieved by Beike Biotech in the field of stem cells. After listening to relevant reports and opinions, Director Dai Tao expressed his views on Beike Biotech’s cutting-edge biomedicine He fully affirmed the work done in innovative R&D and capacity building in the industry, especially in the field of stem cells, fully understood the problems encountered by enterprises in the process of innovation and development, and encouraged Beike Biotech to actively participate in the construction of national health science and technology innovation and development.
Beike Biotechnology has a top stem cell research team and cutting-edge cell storage and preparation technology, innovative and pioneeringThe industrial development model of “comprehensive cell bank + regional cell intelligent manufacturing center + cell quality testing platform” provides an innovative public technology platform and infrastructure for the clinical transformation of cell therapy technology, and also lays a data foundation for the future development layout of artificial intelligence + biomedicine. During this fight against the epidemic, Beike Biotech also actively participated in technical research, and cooperated with Shenzhen Third People’s Hospital (the only designated hospital in Shenzhen to treat patients with new coronavirus pneumonia) to apply for the “Clinical Research on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe Pneumonia Caused by Coronavirus” project (Click to view details), and was approved by the Guangdong Provincial Department of Science and Technology for the 2020 Guangdong Provincial Emergency Response Project for the Prevention and Control of Novel Coronavirus. At the same time, the clinical research on mesenchymal stem cells in the treatment of critically ill patients with new coronavirus pneumonia jointly carried out by Beike Biotech and many medical institutions in Yunnan has also achieved preliminary results, and published the article “Human umbilical cord mesenchymal stem cells combined with antiviral and other methods to treat new coronavirus pneumonia” (Click to view details) to contribute to the fight against the epidemic.